Compare
AOD-9604 vs Semaglutide
Two compounds pursued as pharmacological approaches to weight loss, from opposite starting points and with opposite clinical results. AOD-9604 was designed as a lipolytic fragment of human growth hormone; its 2007 phase 2b did not meet its primary endpoint and its pharmaceutical program was discontinued. Semaglutide came from the incretin research tradition, obtained FDA approval for chronic weight management in 2021, and produced a large clinical evidence base. This page presents the two side by side to make each visible in the other's context.
Last reviewed 2026-07-12
Investigational compound involved
AOD-9604 has never been FDA-approved as a drug for any indication. The GRAS 'no objection' letter that circulates in AOD-9604 marketing is a food-additive-pathway document — not an FDA drug approval. This comparison places the two compounds side by side to make the difference in regulatory position visible; it is not a suggestion that they are clinical equivalents.
Design premise
AOD-9604
A modified 15-amino-acid fragment corresponding to hGH residues 177–191 with an added N-terminal tyrosine. Designed at Monash University in the 1990s to isolate the lipolytic activity of human growth hormone from its growth-signalling activity.
Semaglutide
A long-acting GLP-1 receptor agonist developed by Novo Nordisk, structurally derived from the endogenous incretin GLP-1 with modifications for extended plasma half-life. Not a growth-hormone-derived compound; comes from the incretin research tradition.
Mechanism of action
AOD-9604
Proposed to stimulate lipolysis and inhibit lipogenesis in adipose tissue through the lipolytic domain of hGH's C-terminal region, without engaging the growth-signalling activity of the full-length hormone. Preclinically supported.
Semaglutide
GLP-1 receptor agonism. Increases glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts at central appetite-regulating pathways in the hypothalamus and brainstem to reduce food intake.
2 citations in this row
Pivotal weight-loss trial
AOD-9604
Metabolic Pharmaceuticals 2007 phase 2b: 12 weeks, randomised, placebo-controlled, dose-ranging (0.25 mg to 1 mg subcutaneously daily) in obesity. The primary weight-loss endpoint was NOT MET at any tested dose. The pharmaceutical development program was discontinued after this result.
Semaglutide
STEP-1 (Wilding 2021 NEJM): 68 weeks, randomised, placebo-controlled, semaglutide 2.4 mg subcutaneously weekly in obesity/overweight without diabetes. Mean weight loss ≈14.9% vs 2.4% placebo. Basis of the 2021 FDA approval of Wegovy for chronic weight management.
2 citations in this row
Regulatory status
AOD-9604
Not FDA-approved as a drug for any indication. The pharmaceutical development program was discontinued after the phase 2b did not meet its endpoint. Later received a GRAS 'no objection' letter (2014) for functional-food ingredient use — a food-additive safety pathway, NOT a drug approval and NOT a demonstration of therapeutic efficacy.
Semaglutide
FDA-approved: Ozempic (T2D, 2017; CV risk reduction in T2D + CVD, 2020); Wegovy (chronic weight management, 2021; CV risk reduction in overweight/obesity + CVD, 2024); Rybelsus (oral, T2D, 2019). EMA-approved for the same three brands.
4 citations in this row
Scale of the human evidence base
AOD-9604
Two published human trials: the 12-week phase 2b in obesity (2007, primary endpoint not met) and small intra-articular osteoarthritis pilot work (Kim 2018). No completed phase 3, no post-marketing surveillance dataset — the drug indication does not exist.
Semaglutide
Multiple large randomised trials across STEP (obesity), SUSTAIN (T2D), SELECT (CV outcomes in overweight/obesity), PIONEER (oral), FLOW (renal), STEP-HFpEF (heart failure), and additional programs. Post-marketing surveillance dataset from years of clinical use.
4 citations in this row
How it reaches users
AOD-9604
Research-supply channels and compounding pharmacies for injectable use; functional-food supplement channels citing the GRAS letter for oral use. Neither pathway is an FDA-approved drug supply chain.
Semaglutide
Prescription from a licensed clinician, dispensed through licensed pharmacies. Novo Nordisk-manufactured product; branded delivery devices (Ozempic pen, Wegovy pen). Not lawfully dispensed as a compounded preparation of the branded active ingredient.
2 citations in this row
Competitive-sport status
AOD-9604
On the WADA prohibited list under S2 (peptide hormones, growth factors, related substances and mimetics) as an hGH-derived fragment. A positive test carries doping sanctions regardless of intent.
Semaglutide
Not currently listed as a specifically prohibited substance under WADA's S-classes for GLP-1 agonists as a class. Athletes should verify the current WADA prohibited list before use; the framework is subject to change.
AOD-9604 and semaglutide are not competitors in the same clinical market — one is an approved drug with an established weight-management indication, and the other is a research-supply peptide whose pharmaceutical program ended after a phase 2b that did not meet its endpoint. They are placed side by side here because each makes the other more visible. Semaglutide illustrates what a positive obesity-drug outcome looks like at trial scale; AOD-9604 illustrates why a mechanistically elegant design premise still has to survive a randomised human trial before it becomes a therapy. Reading either without the other risks importing conclusions the evidence base does not support.
References
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta 3-AR knock-out mice· Heffernan M, Summers RJ, Thorburn A, et al. · 2001
- AOD9604 phase 2b clinical trial results in obesity — Metabolic Pharmaceuticals ASX announcement and program disclosure· Metabolic Pharmaceuticals Ltd · 2007
- AOD9604 combined with hyaluronic acid in the treatment of knee osteoarthritis: clinical pilot· Kim MJ, Kim JH, Park SG, et al. · 2018
- GRAS Notice GRN 000501: AOD9604 as an ingredient for use in dietary supplements — FDA 'no objection' response letter· US Food and Drug Administration (GRAS Notice Inventory) · 2014
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide· Lau J, Bloch P, Schäffer L, et al. · 2015
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)· Wilding JPH, Batterham RL, Calanna S, et al. · 2021
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)· Marso SP, Bain SC, Consoli A, et al. · 2016
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)· Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · 2023
- FDA Prescribing Information — OZEMPIC (semaglutide) injection· U.S. Food and Drug Administration · 2017
- FDA Prescribing Information — WEGOVY (semaglutide) injection· U.S. Food and Drug Administration · 2021
- FDA Prescribing Information — RYBELSUS (semaglutide) tablets· U.S. Food and Drug Administration · 2019
Continue exploring
Editorial paths through the library. Pick one and follow the trail.
Compare
Semaglutide vs Tirzepatide
Two of the most extensively studied incretin-based therapies — approved and marketed in the same therapeutic areas, but with different receptor profiles, different phase-3 programs, and different published outcomes. This page compares what the peer-reviewed literature and regulatory documentation currently support for each.
→
Compare
Tirzepatide vs Retatrutide
Two incretin-based peptides in the same broad family, but at very different stages of development. This page compares what the peer-reviewed literature currently supports on each — regulatory status, receptor targets, evidence tier, and headline efficacy from published phase-3 trials.
→
Compare
BPC-157 vs TB-500
These two peptides are the most-discussed pair in the tissue-repair conversation, and they are also the most-conflated. In practice they share none of what usually justifies grouping compounds: their origins are unrelated, their mechanisms are unrelated, and the shape of the evidence supporting each is structurally different. This page walks through those distinctions.
→
Compare
KPV vs GHK-Cu
Two small, endogenously-derived peptides that get grouped in discussions about anti-inflammatory and skin peptides. They share molecular scale — both are tripeptides — and their mechanisms are both proposed to be intracellular rather than classical receptor-mediated. Everything else about their evidence structures, use cases, and regulatory status differs, in ways that are worth reading precisely.
→
Compare
Tesamorelin vs Sermorelin
Two GHRH analogues built for the same fundamental job — stimulating the pituitary's own pulsatile release of growth hormone — but at very different points in structure, half-life, and regulatory history. This page compares what the peer-reviewed literature and regulatory documentation currently support for each.
→
Compare
CJC-1295 (No DAC) vs Sermorelin
Two GHRH(1-29)-based signals. Sermorelin is the native sequence; CJC-1295 No DAC is the same sequence with four amino acid substitutions that resist enzymatic degradation. This page compares what the peer-reviewed literature currently supports on each.
→
Compare
CJC-1295 No DAC vs CJC-1295 DAC
The two forms share an identical GHRH(1-29) backbone with the same four amino acid substitutions. The Drug Affinity Complex (DAC) — a single maleimidopropionic acid linker that covalently binds serum albumin — is the only chemical difference. Every downstream pharmacologic property flows from that one addition. This page reads out those differences precisely.
→
Categories
Fat Loss & Metabolism
Compounds studied for body-composition, glycaemic control, and metabolic health.
→
Categories
Repair & Regeneration
Compounds studied for wound healing, tissue repair, and musculoskeletal recovery.
→